CAMBRIDGE, Mass., May 10, 2010 /PRNewswire via COMTEX News Network/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today reported financial results for the first quarter of 2010. The Company also provided a summary of recent highlights.
"I'm very pleased with the successful first quarter and start to 2010 Verenium had with both its biofuels and specialty enzymes business units," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "Of note, the $5.0 million in gross margin generated from enzyme sales for the quarter is a record for us and is an indication of the strength in that business."
Since the beginning of 2010, Verenium has made significant progress in several important areas, including:
Total revenues for the quarter ended March 31, 2010 were $13.0 million compared to $14.4 million for the same period in the prior year, with product revenues representing 89 percent of total revenues for the three months ended March 31, 2010 compared to 73 percent for the same period in the prior year. Product revenues for the quarter ended March 31, 2010 increased to $11.6 million compared to $10.6 million for same period in the prior year, primarily due to an increase in revenues from the Company's Veretase and Xylathin enzymes, which continued to gain acceptance in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. The Company's Fuelzyme revenues returned to levels achieved in the first quarter of 2009, indicating recovery in the corn ethanol market.
Product gross margin dollars increased to $5.0 million in the first quarter ended March 31, 2010, versus $4.8 million for the same period in the prior year, due primarily to an increase in the royalty on Phyzyme profits received from Danisco, combined with an increase in sales of higher margin enzyme products.
Excluding cost of product revenues, total operating expenses decreased $2.3 million to $24.7 million (including share-based compensation of $0.5 million) for the three months ended March 31, 2010 from $27.0 million (including share-based compensation of $2.5 million) for the three months ended March 31, 2009. Excluding the impact of share-based compensation, total operating expenses decreased $0.3 million for the three months ended March 31, 2010 as compared to the same period in 2009 due to a $0.8 million decrease in expenses related to Vercipia Biofuels, the Company's jointly owned special purpose entity with BP, which was included in the Company's consolidated results of operations during 2009. Effective for 2010, the results of operations for Vercipia are excluded from the Company's consolidated results due to the deconsolidation based upon authoritative new accounting guidance. This decrease in expenses was partially offset by increases in expenses related to the Company's ongoing demonstration-scale facility optimization efforts.
Total operating expenses include gross expenses incurred to support ongoing development related to the Company's Galaxy joint venture with BP, which continues to be consolidated in the Company's financial statements. BP's share of the total operating expenses of the joint ventures was $7.5 million for the first quarter ended March 31, 2010 and $7.9 million for the first quarter ended March 31, 2009, and is included below operating expenses as "Loss attributed to non-controlling interest in consolidated entities" on the Company's Consolidated Income Statement. On a non-GAAP basis, net of BP's share of expenses, pro forma net operating expenses decreased as compared to prior periods, reflecting the cost sharing and the Company's expense minimization efforts.
Interest expense related almost exclusively to the cash and non-cash interest expense from the Company's convertible debt instruments. Of total net interest expense for the first quarter ended March 31, 2010, $0.5 million represents non-cash interest expense related to the Company's convertible notes, compared to $1.6 million in non-cash interest for the same period in 2009.
Net loss attributed to Verenium for the quarter ended March 31, 2010 was $12.0 million compared to net income $3.3 million for the same period in 2009. Adjusted for the non-cash impact of accounting related to the 8% and 9% convertible notes, the Company's non-GAAP pro-forma net loss for the quarter ended March 31, 2010 was $12.7 million compared to $13.6 million for the same period in the prior year. The Company believes that excluding the non-cash impact of these items provides a more consistent measure of operating results.
As of March 31, 2010, the Company had unrestricted cash and cash equivalents totaling approximately $15.5 million compared to $32.1 million as of December 31, 2009. A significant portion of the decrease in cash and cash equivalents is due to the deconsolidation of Vercipia cash and cash equivalents of approximately $7.2 million, based upon authoritative accounting guidance effective on January 1, 2010. In April 2010, the Company was awarded, and collected, an additional $4.9 million from the DOE related to activities at its demonstration-scale facility in Jennings, Louisiana, which is not reflected in the March 31, 2010 cash balance.
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation and project development for next-generation biofuels. Through Vercipia, a 50-50 joint venture with BP, the Company is moving rapidly to commercialize cellulosic technology for the production of ethanol from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to the Company's lines of business, operations, capabilities, commercialization activities, joint ventures, cellulosic ethanol facilities, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with the costs, labor requirements and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaboration, joint venture, manufacturing, and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and laws and regulations applicable to them, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.
Contacts: Kelly Lindenboom Sarah Carmody Vice President, Corporate Communications Manager, Corporate Communications 617-674-5335 617-674-5357 firstname.lastname@example.org email@example.com Verenium Corporation Consolidated Statements of Operations (in thousands, except per share amounts) Three Months Ended March 31, ------------------------- 2010 2009 ---- ---- Revenues: (Unaudited) (Unaudited) Product $11,562 $10,569 Grant 738 2,558 Collaborative 731 1,264 -- ----- Total revenue 13,031 14,391 ----- ------ Operating expenses: Cost of product revenue 6,516 5,755 Research and development 16,999 17,815 Selling, general and administrative 7,698 9,172 ---- ----- Total operating expenses 31,213 32,742 ----- ------ Loss from operations (18,182) (18,351) Interest expense and other, net (1,980) (3,114) Gain on debt extinguishment 598 3,609 Gain on net change in value of derivative assets and liabilities 68 13,309 --- ------ Net loss $(19,496) $(4,547) Loss attributed to non-controlling interest in consolidated entities 7,500 7,870 ----- ----- Net (loss) income attributed to Verenium $(11,996) $3,323 ======== ====== Basic and diluted net (loss) income per share $(0.99) $0.57 ====== ===== Shares used in computing basic net (loss) income per share 12,057 5,857 Shares used in computing diluted net (loss) income per share 12,057 5,866 ====== ===== Note: All share and per share data has been retroactively adjusted for the Company's 1-for-12 reverse stock split, which was effective September 9, 2009. Verenium Corporation Consolidated Balance Sheet Data (in thousands) December March 31, 31, 2010 2009 ---- ---- (Unaudited) (Unaudited) Cash and cash equivalents $15,505 $32,055 Accounts receivable, net 7,668 7,209 Inventory, net 3,621 2,653 Other current assets 4,032 4,657 Restricted cash 10,400 10,400 Property, plant and equipment, net 105,988 108,399 Other noncurrent assets 2,212 2,549 ----- ----- Total assets $149,426 $167,922 ======== ======== Current liabilities, excluding deferred revenue $22,369 $22,967 Deferred revenue 2,599 2,199 Convertible notes, at carrying value 104,101 105,756 Other long term liabilities 6,833 6,798 Stockholders' equity 13,524 30,202 ------ ------ Total liabilities, noncontrolling interests and stockholders' equity $149,426 $167,922 ======== ======== Verenium Corporation Unaudited Supplemental and Non-GAAP Pro Forma Financial Information (in thousands, except per share amounts) Product Gross Margin Three Months Ended March 31, ---------------------------- 2010 2009 ---- ---- (Unaudited) (Unaudited) Product revenues $11,562 $10,569 Cost of product revenues 6,516 5,755 ----- ----- Product gross margin $5,046 $4,814 ====== ====== Three Months Ended March 31, ------------------ 2010 2009 ---- ---- (Unaudited) (Unaudited) Operating expenses (excluding cost of product revenue) $24,697 $26,987 Adjustments: ------------ Loss attributed to non- controlling interest in consolidated entities (7,500) (7,870) ------ ------ Non-GAAP pro forma net operating expenses $17,197 $19,117 ======= ======= Three Months Ended March 31, ------------------------- 2010 2009 ---- ---- (Unaudited) (Unaudited) Net (loss) income attributed to Verenium $(11,996) $3,323 Adjustments: ------------ Gain on debt extinguishment (598) (3,609) Gain on net change in value of derivative assets and liabilities (68) (13,309) --- ------- Non-GAAP pro forma net loss $(12,662) $(13,595) Non-GAAP pro forma net loss per share $(1.05) $(2.32) ====== ======
SOURCE Verenium Corporation
Copyright (C) 2010 PR Newswire. All rights reserved